课题基金 / 基金详情

INFLUENZA VACCINE DEVELOPMENT AND USE

INFLUENZA VACCINE DEVELOPMENT AND USE
流感疫苗的开发和使用
批准号:
3811253
负责人:
R A LEVANDOWSKI
金额:
$0.0万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

R A LEVANDOWSKI的其他基金

相似基金

相关文献

中文摘要
翻译
在1989-1990年流感病毒疫苗中,改变了B组分
英文摘要
For the 1989-1990 influenza virus vaccine the B component was changed because a new strain, B/Yamagata/16/88, appeared in Southeast Asia. Ferrets infected with B/Yamagata and sheep immunized with B/Yamagata vaccine developed hemagglutination inhibition (HI) antibody responses that were not cross-reactive with other influenza B strains including the predominant strain, B/Victoria/2/87. However, data from healthy adults indicated that a broadly reactive HI antibody response could be expected against earlier influenza B virus strains. In order to determine if the antibody response in children was similarly broadly crossreactive, sera were collected from high-risk children who received the commercial trivalent influenza virus vaccine (which included influenza B/Yamagata/16/88). Sera were tested by hemagglutination inhibition and neutralization for antibodies against B/Yamagata/16/88 and B/Victoria/2/87. Two groups of children were immunized: those with a history of previous influenza virus vaccination and those with no history of prior vaccination for influenza. The latter group was younger (mean age 20 months) than the previously immunized group (mean age 29 months). Seven of the 12 previously immunized children had preexisting antibody against influenza B viruses. Reciprocal geometric mean antibody titers (GMT) for these children increased from approximately 8 to 128 for B/Yamagata and from 16 to 128 for B/Victoria. Three of the 11 children not previously immunized had detectable antibody against influenza B viruses. Excluding those three, the children not previously immunized had increases in GMT from <8 to 128 for B/Yamagata but no change in titer for B/Victoria (pre and post GMT <8). There was an extremely good correlation between HI with detergent disrupted virus and neutralizing antibody titer. For all sera the data suggest that immunologically primed but not unprimed children develop a cross reactive antibody response after immunization with an influenza B virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DEVELOPMENT, STANDARDIZATION AND USE OF INFLUENZA VIRUS VACCINES
  • 批准号:
    3748167
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    R A LEVANDOWSKI
  • 依托单位:
    --
INFLUENZA VACCINE DEVELOPMENT AND USE
  • 批准号:
    3804805
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    R A LEVANDOWSKI
  • 依托单位:
    --
INFLUENZA REASSORTANT VIRUS--BIOLOGY AND GENETICS
  • 批准号:
    3804809
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    R A LEVANDOWSKI
  • 依托单位:
    --
CELLULAR AND HUMORAL IMMUNE RESPONSES TO RHINOVIRUSES
  • 批准号:
    3811252
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    R A LEVANDOWSKI
  • 依托单位:
    --
海外基金